The Supreme Court had rejected the Novartis’ appeal for a patent on Glivec (Imatinib Mesylate), a drug that treats chronic myloid leukemia on April 1, 2013. The ground on which it was rejected was Section 3(d) of the Indian patent law that says new forms of existing medicines cannot be patented unless …
